VRDN

Business Context and Reporting Period

Company: Viridian Therapeutics, Inc. (VRDN)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Viridian is a biopharmaceutical company focused on developing medicines for serious and rare diseases, primarily targeting Thyroid Eye Disease (TED) and autoimmune disorders via FcRn inhibition. The company has no approved products and has not generated revenue from product sales.

Key Financial Metrics

Note: The company reported $176.3 million in cash and cash equivalents and $585.8 million in marketable securities as of March 31, 2026.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased to $141,000 from $72,000, driven by $135,000 in collaboration revenue from related parties (Zenas BioPharma/Zai Lab) and $6,000 in license revenue.
• Expense Increases: SG&A expenses surged by $21.6 million (126% increase) to $38.7 million, primarily due to increased headcount and professional fees to support preparatory commercial activities for veligrotug. R&D expenses remained relatively flat, increasing slightly by $0.8 million.
• Net Loss Expansion: Net loss widened by $18.0 million to $104.9 million, reflecting the significant rise in operating expenses.
• Derivative Liability Gain: The company recognized a $7.5 million gain from the change in fair value of a derivative liability associated with its revenue participation agreement, partially offsetting the net loss.
• Liquidity Position: Cash and marketable securities totaled $762.2 million as of March 31, 2026, providing a runway of at least 12 months.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Veligrotug (IV): A Biologics License Application (BLA) was submitted to the FDA in October 2025 and granted Priority Review with a PDUFA target action date of June 30, 2026. A Marketing Authorization Application (MAA) was submitted to the EMA in January 2026.
• Elegrobart (SC): Topline data from Phase 3 trials (REVEAL-1 and REVEAL-2) were announced in March and May 2026, meeting primary endpoints. A BLA submission is anticipated in Q1 2027.
• Capital Resources: Management expects current cash, marketable securities, and potential near-term milestone payments (up to $75 million under the DRI agreement) to fund operations through at least the next 12 months.

Risks and Contingencies

• Regulatory Delays: Risks include potential FDA disruptions due to government shutdowns or policy changes, which could delay the June 2026 PDUFA date for veligrotug.
• Manufacturing Dependencies: The company relies on third-party manufacturers, including WuXi Biologics in China. The BIOSECURE Act and geopolitical tensions pose risks to the supply chain.
• Debt Covenants: The company has a $300 million term loan facility with Hercules Capital (currently $50 million drawn) and a revenue participation agreement with DRI Healthcare. Failure to meet milestones could impact future funding availability.
• Going Concern: While the company currently has sufficient liquidity, it has an accumulated deficit of $1.44 billion and expects to continue incurring losses until product approval and commercialization.

Investor Verification Checklist

• Regulatory Timeline: Verify the status of the veligrotug BLA review and the June 30, 2026 PDUFA date, considering potential FDA operational disruptions.
• Clinical Data Finalization: Confirm that final audited data from the REVEAL-1 and REVEAL-2 trials for elegrobart align with the announced topline results.
• Supply Chain Resilience: Assess the impact of the BIOSECURE Act and reliance on Chinese CDMOs (WuXi) on the ability to manufacture commercial supplies.
• Debt Milestones: Monitor the achievement of regulatory milestones required to unlock additional tranches under the Hercules loan and the DRI revenue participation agreement.
• Commercial Readiness: Evaluate the company's progress in building sales and marketing infrastructure to support a potential launch in 2026/2027.